The blood-brain barrier (BBB) is one of the most essential protection mechanisms in the
central nervous system (CNS). It selectively allows individual molecules such as small lipid …

Obtaining efficient drug delivery to the brain remains the biggest challenge for the
development of therapeutics to treat diseases of the central nervous system. The main …

Bionanotechnology has now become firmly established in its own right as one of the
principle and focused subdisciplines within nanotechnology.(1-10) Bionanotechnology can …

The central nervous system, one of the most delicate microenvironments of the body, is
protected by the blood‐brain barrier (BBB) regulating its homeostasis. BBB is a highly …

Alzheimer's disease (AD) is a progressive deterioration of brain function, initially
characterized by cognitive deficits, with loss of recent memory and language ability …

A variety of neuroprotectants have shown promise in treating ischemic stroke, yet their
delivery to the brain remains a challenge. The endothelial cells lining the blood-brain barrier …

This paper highlights the importance of lipid-based colloidal carriers and their
pharmaceutical implications in the delivery of peptides and proteins for oral and parenteral …

Although various peptide and protein drugs have been developed for therapeutic purposes,
several challenges can still be encountered, including a relatively short half-life within the …

The central nervous system (CNS) is a sanctuary site and is protected by various barriers.
These regulate brain homeostasis and the transport of endogenous and exogenous …

Alzheimer's disease (AD) is an incurable neurological illness and the leading cause of
dementia, characterized by amyloid β (Aβ) fibril deposits. Caffeic acid (CA) has …